Apolipoprotein E-Alpha-1 Antitrypsin promoter (ApoE-hAAT promoter)

The Apolipoprotein E-Alpha-1 Antitrypsin (ApoE-hAAT) promoter is a synthetic, chimeric DNA regulatory element engineered for liver-directed gene therapy. It typically incorporates the hepatic control region (HCR) enhancer from the human Apolipoprotein E (ApoE) gene locus fused to the human Alpha-1 Antitrypsin (hAAT, also known as SERPINA1) core promoter [1, 2, 3]. This combination restricts the expression of a linked transgene specifically to hepatocytes, ensuring high-level production and secretion of therapeutic proteins into the systemic circulation while minimizing off-target activity in other tissues [3, 10]. The ApoE-hAAT promoter is a critical component of modern genetic medicines, serving as the transcriptional engine for the FDA-approved gene therapy fidanacogene elaparvovec (Beqvez) for Hemophilia B, as well as several clinical-stage candidates for metabolic and hematological disorders [1, 6]. While not a conventional drug target such as a receptor or enzyme, its optimization in terms of potency, size, and liver specificity is fundamental to the safety and clinical efficacy of viral vector-based treatments [1, 4]. Safety considerations primarily involve maintaining strict tissue specificity to avoid unintended systemic toxicity or immunogenicity against the transgene product [4, 6].

Other names

ApoE/hAATHCR-hAATApolipoprotein E enhancer-Alpha-1 Antitrypsin promoterApoE-HCR/hAATApoE-SERPINA1 promoterLP1 promoter (related)HLP (Hybrid Liver Promoter, related)

Initiation of high-level, hepatocyte-restricted transcription of a downstream transgene through the synergistic recruitment of liver-specific transcription factors to the ApoE enhancer and hAAT core promoter elements.